Filing summary: Angion Biomedica Corp. Form 10-Q, quarter ended June 30, 2022
Entity mismatch: The request identifies Elicio Therapeutics, Inc., but the supplied filing is for Angion Biomedica Corp. (Nasdaq: ANGN). This summary reflects the supplied Angion filing, not an Elicio filing.
Business context and reporting period
This unaudited Form 10-Q covers the three and six months ended June 30, 2022; it was signed August 15, 2022. Angion was a clinical-stage biopharmaceutical company with no approved products and no product-sale revenue. Its reported revenue came from contract/license activity.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $0.65 million | $0.54 million | $2.30 million | $0.91 million |
| Research and development expense | $6.07 million | $14.44 million | $17.74 million | $28.74 million |
| General and administrative expense | $3.62 million | $4.34 million | $8.08 million | $10.35 million |
| Net loss | $9.14 million | $17.07 million | $23.38 million | $53.76 million |
| Net loss per share, basic and diluted | $0.30 | $0.58 | $0.78 | $2.02 |
| Cash used in operating activities | — | $25.56 million | $23.08 million |
At June 30, 2022, cash and cash equivalents were $63.37 million, down from $88.76 million at December 31, 2021. Total current assets were $65.89 million and current liabilities $7.78 million. Total liabilities were $11.05 million, including lease liabilities and a $0.26 million financing obligation; the filing reports no convertible notes outstanding. Stockholders’ equity was $59.76 million and accumulated deficit was $238.51 million. The filing states cash was expected to fund planned operations for at least 12 months following issuance of the statements, while noting that projections could prove inaccurate and that requirements were difficult to estimate during the strategic process.
Changes versus comparable periods
- Q2 revenue rose 21%, while operating expenses fell 48% and net loss narrowed by $7.93 million year over year. For the first half, revenue rose 153%, operating expenses fell 34%, and net loss narrowed by $30.38 million.
- Lower R&D spending reflected reduced clinical-trial activity and the January 2022 workforce reduction; lower G&A reflected reduced personnel costs. The first-half results included about $3.2 million of January restructuring costs.
- Revenue recognition accelerated as Angion reassessed its remaining work under the Vifor license. It recognized the remaining $2.3 million of deferred revenue in the first half; no deferred revenue remained at June 30.
- Operating cash use increased to $25.56 million from $23.08 million in the first half of 2021. The prior-year period included $106.07 million of net financing cash inflows, primarily from the IPO and concurrent private placement; there were no comparable proceeds in 2022.
Outlook, risks, contingencies, and unusual items
- Angion announced after quarter-end, on July 25, 2022, that it would explore strategic alternatives, potentially including a merger, reverse merger, other business combination, asset sale, or licensing transaction. It disclosed no assurance that a transaction would be completed.
- The company discontinued ANG-3070 development across indications and paused other development activities pending the strategic process, except certain ANG-3777 preclinical studies. It expected a further workforce reduction affecting most of its 37 employees and an approximately $3.3 million charge in Q3 2022.
- ANG-3777 Phase 3 testing in delayed graft function and Phase 2 testing in cardiac-surgery-associated acute kidney injury failed their primary endpoints. Angion said it did not expect further clinical, approval, or sales milestones or royalties under the Vifor license based on its decision not to continue the planned clinical development program.
- Management reported no material legal proceedings and concluded there was no substantial doubt about the company’s ability to continue as a going concern for at least one year after issuance. These conclusions depend on assumptions, including cash needs during the strategic process.
- Disclosure controls and procedures were deemed ineffective at June 30 because of material weaknesses involving technical accounting resources and expense-accrual/close controls. Remediation was ongoing; management said additional procedures supported the fair presentation of the reported statements.
- The filing highlighted risks including failure or delay in completing a strategic transaction, restructuring costs and operational disruption, and possible Nasdaq listing noncompliance if the stock-price requirement is not met.
Important facts for investors to verify
- Confirm the filing entity: the supplied report is Angion Biomedica Corp., not Elicio Therapeutics, Inc.
- Review the outcome, timing, costs, and funding implications of the strategic-alternatives process and workforce reduction.
- Assess cash runway against continuing operating, public-company, restructuring, and transaction costs; the stated 12-month estimate is based on assumptions.
- Check subsequent disclosures about the Vifor collaboration, ANG-3777 work, and any potential remaining payments.
- Monitor remediation and testing of the disclosed material weaknesses, as well as Nasdaq listing compliance.